Dimethaid appoints new CEO
TORONTO, Sept. 22 /CNW/ - Pharmaceutical developer Dimethaid Research
Inc. (TSX: DMX) has announced the appointment of Dr. Henrich R.K. Guntermann
as president and chief executive officer. Dr. Guntermann was elected director
at the company's annual general meeting, held September 21, 2004.
Dr. Guntermann is a medical doctor with over ten years experience in the
health care sector including business development, restructuring and corporate
finance. He has also worked as a clinician and researcher at the University
Hospital in Zurich, Switzerland. In 1998, Dr. Guntermann co-founded
BioAlliance AG, a German life sciences private equity and consulting firm.
Dr. Guntermann received his medical doctorate at the Philipps-University
in Marburg, Germany. He has also received a masters of science in biology,
with specialization in pharmacology/toxicology and human genetics.
Dr. Guntermann is in the process of relocating to Canada.
In addition, Daniel H. Chicoine has been appointed chairman of the board
and John C. London has been appointed corporate secretary.
The company has also formed a Corporate Governance and Compensation
Committee, consisting of Dr. Klaus von Lindeiner, John C. London and
Dr. Jacques Messier. Members of the Audit and Environmental Committee include
Dr. Klaus von Lindeiner, David A. Copeland and Anthony E. Dobranowski. |
